Benedyk A, Moldavski A, Reichert M, Reinhard I, Fritze S, Tost H, Meyer-Lindenberg A. Shared and distinct effects of everyday physical activity on affective well-being in schizophrenia, major depression, and healthy controls. J Psychopathol Clin Sci. 2025 Jul 24. [Epub ahead of print]
Berger M, Garcia-Moreno H, Ferreira M, Hubener-Schmid J, Schaprian T, Wegner P, Elter T, Teichmann KM, Santana MM, Grobe-Einsler M, Oender D, Koyak BSC, Bernsen S, Pereira de Almeida L, Silva P, Ribeiro JA, Cunha I, Gonzalez-Robles C, Khan S, Heslegrave A, Zetterberg H, Lima M, Raposo M, Ferreira AF, Vasconcelos J, van de Warrenburg BP, van Gaalen J, van Prooije TH, de Vries J, Schols L, Riess O, Synofzik M, Timmann D, Thieme A, Erdlenbruch F, Infante J, Pelayo-Negro AL, Manrique L, Reetz K, Dogan I, Oz G, Joers JM, Bushara K, Onyike C, Považan M, Jacobi H, Schmahmann JD, Ratai EM, Schmid M, Giunti P, Klockgether T, Faber J. Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort. Lancet Reg Health Eur. 2025 55:101339.
Ludwig VM, Bittendorf CA, Reinhard I, Guth M, Mühlbauer E, Hartnagel LM, Severus WE, Bauer M, Ritter P, Ebner-Priemer U. Predicting depressive and manic episodes in patients with bipolar disorder using statistical process control methods on passive sensing data. J Psychopathol Clin Sci. 2025 Jul 21. [Epub ahead of print]
Ludwig VM, Bittendorf CA, Reinhard I, Neubauer AB, Mennigen E, Mühlbauer E, Severus WE, Bauer M, Ebner-Priemer U. Early warning signs of bipolar relapse: Investigating critical slowing down in smartphone data. J Affect Disord. 2025 391:119972. Epub 2025 Jul 28.
Möhring C, Berger M, Sadeghlar F, Zhou X, Zhou T, Monin MB, Shmanko K, Welland S, Sinner F, Schwacha-Eipper B, Bauer U, Roderburg C, Pirozzi A, Ben Khaled N, Schrammen P, Balcar L, Pinter M, Ettrich TJ, Saborowski A, Berres ML, De Toni EN, Lüdde T, Rimassa L, Ehmer U, Venerito M, Radu IP, Schmidt-Wolf IGH, Weinmann A, Vogel A, Schmid M, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study. Cancers (Basel). 2025 17(6)